R&G PharmaStudies Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	896.26	851.01	744	721.37	637.52	608.43
Revenue Growth (YoY)	21.20%	14.38%	3.14%	13.15%	4.78%	25.59%
Cost of Revenue	597.9	555.36	468.08	434.34	402.62	375.25
Gross Profit	298.35	295.64	275.92	287.04	234.9	233.17
Selling, General & Admin	101.77	102	91.29	94.45	75.34	71.85
Research & Development	63.01	61.97	56.83	52.86	49.99	41.19
Other Operating Expenses	3.71	3.98	3.39	3.76	3.01	3.43
Operating Expenses	173.68	173.13	154.88	155.93	131.92	124.02
Operating Income	124.68	122.51	121.05	131.11	102.98	109.15
Interest Expense	-2.86	-2.86	-3.44	-0.6	-0.67	-0.58
Interest & Investment Income	19.67	21.25	23.17	34.6	15.04	5.46
Currency Exchange Gain (Loss)	-3.47	-3.47	1.72	1.38	5.73	-1.34
Other Non Operating Income (Expenses)	-2.29	-0.38	-1.79	-0.35	-0.58	-0.41
EBT Excluding Unusual Items	135.72	137.05	140.7	166.14	122.5	112.28
Gain (Loss) on Sale of Investments	9.76	10.95	11.28	3.98	0.91	-2.1
Gain (Loss) on Sale of Assets	-0.01	-0.01	-0.07	-0.02	-0.02	-0.02
Asset Writedown	-0.9	-	-	-	-	-
Other Unusual Items	7.16	7.16	5.87	12.37	5.5	3.44
Pretax Income	151.74	155.15	157.79	182.47	128.89	113.6
Income Tax Expense	16.97	16.85	16	19.61	14.75	13.24
Earnings From Continuing Operations	134.77	138.29	141.79	162.86	114.13	100.35
Minority Interest in Earnings	-1.12	-1.39	-1.57	-0.33	-0.69	-1.12
Net Income	133.65	136.9	140.22	162.53	113.45	99.24
Net Income to Common	133.65	136.9	140.22	162.53	113.45	99.24
Net Income Growth	-6.70%	-2.37%	-13.73%	43.27%	14.32%	18.37%
Shares Outstanding (Basic)	95	96	95	96	82	72
Shares Outstanding (Diluted)	95	96	95	96	82	72
Shares Change (YoY)	-0.16%	0.36%	-0.64%	16.78%	14.43%	-0.38%
EPS (Basic)	1.40	1.43	1.47	1.69	1.38	1.38
EPS (Diluted)	1.40	1.43	1.47	1.69	1.38	1.38
EPS Growth	-6.55%	-2.72%	-13.17%	22.68%	-0.09%	18.82%
Free Cash Flow	88.52	94.93	134.78	172.68	109.64	76.29
Free Cash Flow Per Share	0.93	0.99	1.41	1.80	1.33	1.06
Dividend Per Share	0.160	0.160	0.160	0.200	0.156	-
Dividend Growth	-	-	-20.00%	27.96%	-	-
Gross Margin	33.29%	34.74%	37.09%	39.79%	36.85%	38.32%
Operating Margin	13.91%	14.40%	16.27%	18.18%	16.15%	17.94%
Profit Margin	14.91%	16.09%	18.85%	22.53%	17.79%	16.31%
Free Cash Flow Margin	9.88%	11.15%	18.12%	23.94%	17.20%	12.54%
EBITDA	127.36	129.32	144.37	153.73	110.43	135.31
EBITDA Margin	14.21%	15.20%	19.40%	21.31%	17.32%	22.24%
D&A For EBITDA	2.68	6.81	23.32	22.62	7.44	26.16
EBIT	124.68	122.51	121.05	131.11	102.98	109.15
EBIT Margin	13.91%	14.40%	16.27%	18.18%	16.15%	17.94%
Effective Tax Rate	11.18%	10.86%	10.14%	10.75%	11.45%	11.66%
Revenue as Reported	851.01	851.01	744	721.37	637.52	608.43
Advertising Expenses	-	-	-	-	-	1.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.